Hormonal
Administration of recombinant human Fibroblast Growth Factor 19 (FGF19) increases metabolic rate and reverses diet-induced and leptin-deficient diabetes in mice without reducing food intake.
This research identifies FGF19, a hormone, as a potent driver of metabolic rate and glucose control in mice. While not a current human supplement, it suggests that targeting FGF19 pathways could be a viable strategy for treating obesity and type 2 diabetes by increasing energy expenditure rather than restricting food intake.
In mice fed a high-fat diet, human fibroblast growth factor 19 (FGF19) increased metabolic rate... and decreased respiratory quotient... FGF19-treated mice lost weight... without a significant change in food intake. Furthermore... treatment with FGF19 prevented or reversed the diabetes that develops in mice made obese by genetic ablation of brown adipose tissue or genetic absence of leptin.
Why this rating
High-quality controlled animal study with multiple models (HFD, ob/ob, UCP-DTA) and rigorous metabolic measurements.
Source
Fibroblast Growth Factor 19 Increases Metabolic Rate and Reverses Dietary and Leptin-Deficient Diabetes
Ling Fu et al. · Endocrinology · 2004
DOI 10.1210/en.2003-1671
More from this paper
- FGF19 increases metabolic rate and improves glucose homeostasis by increasing fatty acid oxidation and decreasing liver triglycerides, mediated by the suppression of Acetyl CoA Carboxylase 2 (ACC2) and increased leptin receptor expression in the liver.Good
- Brown Adipose Tissue (BAT) activation is not essential for FGF19 to increase metabolic rate and reverse obesity/diabetes, as FGF19 remains effective in mice with diminished BAT (UCP-DTA mice).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →